XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Apr. 15, 2024
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Jun. 30, 2023
Accounting Policies [Line Items]            
Marketable Securities, Current   $ 6,499   $ 6,499   $ 38,540
Marketable securities, non-current   0   0   4,497
Total Marketable Securities   6,499   6,499   43,037
Unrealized Loss on Securities       (29) $ 370  
Investments, Fair Value Disclosure   $ 6,470   6,470   42,667
Stock Repurchased and Retired During Period, Shares   1,085,574        
Purchase of ordinary shares   $ 100,729   100,729    
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net [1]   9,071 $ (2,428) 3,715 2,021  
Foreign Currency Transaction Gain (Loss), Realized [2]   (12,434) 4,187 (2,071) 10,217  
Other Nonoperating Gains (Losses)   (288) (382) 733 (856)  
Other (expense) income, net   (3,651) 1,377 2,377 11,382  
Realized gain (loss) on derivatives not designated as hedging instruments   349 $ 4,876 838 $ 35,864  
Accounts Payable, Other   $ 52,555   $ 52,555   44,522
Net Income (Loss) Per Share Attributable to Cimpress plc [Line Items]            
Weighted average shares outstanding — basic   26,216,216 26,268,301 26,432,423 26,226,989  
Weighted average shares issuable upon exercise/vesting of outstanding share options/RSUs/warrants (1)(2) [3],[4]   0 0 711,196 0  
Weighted average shares outstanding — diluted   26,216,216 26,268,301 27,143,619 26,226,989  
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount [3]   955,594 3,161,275 127,229 3,045,675  
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements     309,000   184,608  
Long-Lived Assets Held-for-Sale [Line Items]            
Long-Lived Asset, Held-for-Sale, Fair Value Disclosure   $ 16,595   $ 16,595    
Commercial Paper            
Accounting Policies [Line Items]            
Marketable Securities, Current           15,982
Unrealized Loss on Securities         $ 10  
Investments, Fair Value Disclosure           15,972
Corporate Debt Securities            
Accounting Policies [Line Items]            
Marketable Securities, Current   2,500   2,500   16,298
Marketable securities, non-current           1,498
US Government Debt Securities [Member]            
Accounting Policies [Line Items]            
Marketable securities, non-current           2,999
Foreign Exchange Forward [Member]            
Accounting Policies [Line Items]            
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net   9,071 $ (2,428) 3,715 2,021  
Marketable securities, current [Member]            
Accounting Policies [Line Items]            
Unrealized Loss on Securities         269  
Investments, Fair Value Disclosure           38,271
Marketable securities, current [Member] | Corporate Debt Securities            
Accounting Policies [Line Items]            
Unrealized Loss on Securities       11 190  
Investments, Fair Value Disclosure   2,489   2,489   16,108
Marketable securities, current [Member] | US Government Debt Securities [Member]            
Accounting Policies [Line Items]            
Marketable Securities, Current   3,999   3,999   6,260
Unrealized Loss on Securities       18 69  
Investments, Fair Value Disclosure   $ 3,981   $ 3,981   6,191
Marketable securities, noncurrent [Member]            
Accounting Policies [Line Items]            
Unrealized Loss on Securities         101  
Investments, Fair Value Disclosure           4,396
Marketable securities, noncurrent [Member] | Corporate Debt Securities            
Accounting Policies [Line Items]            
Unrealized Loss on Securities         35  
Investments, Fair Value Disclosure           1,463
Marketable securities, noncurrent [Member] | US Government Debt Securities [Member]            
Accounting Policies [Line Items]            
Unrealized Loss on Securities         $ 66  
Investments, Fair Value Disclosure           $ 2,933
Subsequent Event [Member]            
Long-Lived Assets Held-for-Sale [Line Items]            
Proceeds from Sale, Property, Held-for-Sale $ 16,785          
[1] Includes realized and unrealized gains and losses on derivative currency forward and option contracts not designated as hedging instruments. For contracts not designated as hedging instruments, we realized losses of $349 and $838 for the three and nine months ended March 31, 2024, respectively, and realized gains of $4,876 and $35,864 for the three and nine months ended March 31, 2023, respectively. Refer to Note 4 for additional details relating to our derivative contracts.
[2] Currency-related (losses) gains, net primarily relates to significant non-functional currency intercompany financing relationships that we may change at times and are subject to currency exchange rate volatility. In addition, we have a cross-currency swap designated as a cash flow hedge which hedges the remeasurement of an intercompany loan. Refer to Note 4 for additional details relating to this cash flow hedge.
[3] In the periods in which a net loss is recognized, the impact of share options, RSUs and warrants is excluded from shares used in computed diluted net (loss) income per share as it is anti-dilutive. Any equity awards that have a performance condition are not included in dilutive or anti-dilutive shares until the performance condition is met.
[4] On May 1, 2020, we entered into a financing arrangement which included 7-year warrants to purchase 1,055,377 of our ordinary shares with a strike price of $60 that have a potentially dilutive impact on our weighted average shares outstanding. For the three and nine months ended March 31, 2024, the average market price of our ordinary shares was higher than the strike price of the warrants. The weighted average anti-dilutive effect of the warrants was 309,000 for the three months ended March 31, 2024 (anti-dilutive due to our net loss position), and the weighted average dilutive effect of the warrants was 184,608 for the nine months ended March 31, 2024. For the three and nine months ended March 31, 2023, the average market price of our ordinary shares was lower than the strike price of the warrants; therefore, the total 1,055,377 outstanding warrants were considered anti-dilutive.